Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients

Journal of the Formosan Medical Association

Volumn 102, Issue 6, 2003, Pages 407-411

  Chang, Gee Chen ^a,b   Yang, Tsung Ying ^a   Wang, Nai San ^c   Huang, Chih Mei ^a   Chiang, Chi Der ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c National Tai Chung Institute of Technology   (Taiwan)

Author keywords

Adenocarcinoma, bronchiolo alveolar; Case report; Quinazolines; Receptor, epidermal growth factor; ZD1839

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TUBERCULOSTATIC AGENT; ANTINEOPLASTIC AGENT;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CANCER CELL; CANCER PATIENT; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE DURATION; DRY SKIN; DYSPNEA; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG BIOPSY; LUNG INFILTRATE; LUNG LAVAGE; NASOGASTRIC TUBE; NUCLEAR MAGNETIC RESONANCE IMAGING; RESPIRATORY FAILURE; SPINE SURGERY; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME; AGED; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 0142168033     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 1995;75: 191-202.
2. Feldman ER, Eagan RT, Schaid DJ: Metastatic bronchioalveolar carcinoma and metastatic adenocarcinoma of the lung: comparison of clinical manifestations, chemotherapeutic responses, and prognosis. Mayo Clin Proc 1992;67:27-32.
3. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
4. Fontanini G, Vignati S, Bigini D, et al: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995;31A: 178-83.
5. Mukaida H, Toi M, Hira T, et al: Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991;68:142-8.
6. Neal DE, Marsh C, Bennett MK, et al: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366-8.
7. Sainsbury JR, Farndon JR, Needham GK, et al: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987;1:1398-402.
8. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
9. Arteaga CL, Johnson DH: Tyrosine kinase inhibitors-ZD 1839 (Iressa). Curr Opin Oncol 2001;13:491-8.
10. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
11. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
12. Ranson M, Hammon LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitors, is well tolerated and active in patients with solid, malignant tumors: results of a phase trial. J Clin Oncol 2002;20:2240-50.
13. Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003, 14:922-30.
14. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). In: Proceedings of the American Society of Clinical Oncology (ASCO). Alexandria, Va: ASCO; 2002:21.
15. Travis WD, Colby TV, Corrin B: Histological typing of lung and pleural tumors, 3rd ed. Berlin: Springer Verlag; 1999.
16. Clayton F: Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer 1986;57:1555-64.
17. Daly RC, Trastek VF, Pairolero PC, et al: Bronchoalveolar carcinoma: factors affecting survival. Ann Thorac Surg 1991; 51:368-76.
18. Clayton F: The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu 1988;23:361-94.
19. Delarue NC, Anderson W, Sanders D, et al: Bronchiolo-alveolar carcinoma. A reappraisal after 24 years. Cancer 1972;29:90-7.
20. Ludington LG, Verska JJ, Howard T, et al: Bronchiolar carcinoma (alveolar cell), another great imitator; a review of 41 cases. Chest 1972;61:622-8.
21. Cox G, Jonees JL, O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.
22. Veale D, Ashcroft T, Marsh C, et al: Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987;55: 513-6.
23. Ohsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-7.
24. Pfeiffer P, Nexo E, Bentzen SM, et al: Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 1998; 78:96-9.
25. Janne PA, Ostler PA, Lucca J, et al: ZD1839 ("Irressa") shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol In: Proceedings of the American Society of Clinical Oncology (ASCO). Alexandria, Va: ASCO; 2002;21.
26. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
27. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res 2002;62:5749-54.